ES2118992T3 - Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion. - Google Patents

Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Info

Publication number
ES2118992T3
ES2118992T3 ES94102557T ES94102557T ES2118992T3 ES 2118992 T3 ES2118992 T3 ES 2118992T3 ES 94102557 T ES94102557 T ES 94102557T ES 94102557 T ES94102557 T ES 94102557T ES 2118992 T3 ES2118992 T3 ES 2118992T3
Authority
ES
Spain
Prior art keywords
compounds
procedure
preparation
cyclic derivatives
medicines containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94102557T
Other languages
English (en)
Inventor
Frank Dr Dipl-Chem Himmelsbach
Helmut Dr Dipl-Chem Pieper
Volkhard Prof Dr Dipl-C Austel
Gunter Dr Dipl-Chem Linz
Brian Dr Guth
Thomas Dr Arzt Und Dipl Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4305388A external-priority patent/DE4305388A1/de
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Application granted granted Critical
Publication of ES2118992T3 publication Critical patent/ES2118992T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS COMPONENTES AZABICICLICOS, LOS CUALES SON SUSTITUIDOS MEDIANTE UN GRUPO UREICO CICLICO, O SUS DERIVADOS, COMO P.EJ. EL COMPONENTE (VER FORMULA), POSEEN EFECTOS INHIBIDORES DE LA AGREGACION DE CELULAS, Y PUEDEN SER PRODUCIDOS COMO MEDICAMENTOS INHIBIDORES DE INFLAMACIONES O TUMORES ASI COMO MEDICAMENTOS ANTITROMBOTICAS.
ES94102557T 1993-02-22 1994-02-21 Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion. Expired - Lifetime ES2118992T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4305388A DE4305388A1 (de) 1993-02-22 1993-02-22 Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4332168A DE4332168A1 (de) 1993-02-22 1993-09-22 Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ES2118992T3 true ES2118992T3 (es) 1998-10-01

Family

ID=25923309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94102557T Expired - Lifetime ES2118992T3 (es) 1993-02-22 1994-02-21 Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Country Status (22)

Country Link
US (3) US5519036A (es)
EP (1) EP0612741B1 (es)
JP (1) JP3545446B2 (es)
KR (1) KR100322319B1 (es)
CN (1) CN1048490C (es)
AT (1) ATE167185T1 (es)
AU (1) AU673875B2 (es)
CA (1) CA2116068A1 (es)
CZ (1) CZ37494A3 (es)
DE (2) DE4332168A1 (es)
DK (1) DK0612741T3 (es)
ES (1) ES2118992T3 (es)
FI (1) FI940806L (es)
HU (1) HU222112B1 (es)
IL (1) IL108733A (es)
MX (1) MX9401315A (es)
NO (1) NO305081B1 (es)
NZ (1) NZ250944A (es)
PH (1) PH30602A (es)
PL (1) PL178215B1 (es)
SG (1) SG52300A1 (es)
UA (1) UA39099C2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19624069A1 (de) * 1996-06-17 1997-12-18 Thomae Gmbh Dr K Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE4424974A1 (de) * 1994-07-15 1996-01-18 Thomae Gmbh Dr K Harnstoff- und Carbaminsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4427838A1 (de) * 1994-08-05 1996-02-08 Thomae Gmbh Dr K Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de) * 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EE9700141A (et) * 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5925635A (en) * 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
US6340687B1 (en) 1997-09-03 2002-01-22 American Home Products Corporation Substituted tetrahydro-pyrimidine-2(1H)-thione HDL-C elevators useful as antiatherosclerotic agents
AU753675B2 (en) * 1998-03-19 2002-10-24 Ajinomoto Co., Inc. Aminoisoquinoline derivatives
AU3631500A (en) * 1999-03-19 2000-10-09 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
ATE410165T1 (de) 2001-04-18 2008-10-15 Euro Celtique Sa Nociceptin-analoga
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
CA2495589A1 (en) * 2002-08-14 2004-02-26 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
PT1572215E (pt) 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1799684B1 (en) * 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CA2655574A1 (en) 2006-06-20 2007-12-27 Wyeth Imidazole kv1.5 potassium channel inhibitors
WO2008009125A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US7998952B2 (en) 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP4352062A4 (en) * 2021-05-05 2025-05-14 Diamond Therapeutics Inc. 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106571D0 (en) * 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4112014A1 (de) * 1991-04-12 1992-10-15 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation

Also Published As

Publication number Publication date
HU9400493D0 (en) 1994-05-30
AU673875B2 (en) 1996-11-28
NO940595D0 (no) 1994-02-21
KR940019704A (ko) 1994-09-14
DK0612741T3 (da) 1999-03-29
EP0612741B1 (de) 1998-06-10
IL108733A (en) 1998-01-04
US5612335A (en) 1997-03-18
MX9401315A (es) 1994-08-31
IL108733A0 (en) 1994-05-30
CZ37494A3 (en) 1994-12-15
PL178215B1 (pl) 2000-03-31
NZ250944A (en) 1996-02-27
ATE167185T1 (de) 1998-06-15
HUT70768A (en) 1995-10-30
DE59406157D1 (de) 1998-07-16
CN1099755A (zh) 1995-03-08
JP3545446B2 (ja) 2004-07-21
JPH06256343A (ja) 1994-09-13
SG52300A1 (en) 1998-09-28
DE4332168A1 (de) 1995-03-23
US5827849A (en) 1998-10-27
US5519036A (en) 1996-05-21
CN1048490C (zh) 2000-01-19
PH30602A (en) 1997-07-31
CA2116068A1 (en) 1994-08-23
FI940806A7 (fi) 1994-08-23
FI940806L (fi) 1994-08-23
AU5632494A (en) 1994-08-25
NO940595L (no) 1994-08-23
UA39099C2 (uk) 2001-06-15
HU222112B1 (hu) 2003-04-28
FI940806A0 (fi) 1994-02-21
KR100322319B1 (ko) 2002-06-26
NO305081B1 (no) 1999-03-29
EP0612741A1 (de) 1994-08-31

Similar Documents

Publication Publication Date Title
AR003937A1 (es) Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES2074429T3 (es) Derivados de fluorocitidina, su preparacion y preparados medios que los contienen.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
MX9203438A (es) Metodo para inhibir el crecimiento de celulas progenitoras.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
ES8102131A1 (es) Procedimiento para preparar una composicion oral que com- prende un compuesto de 2-penem
ES2190430T3 (es) Nuevas sulfonamidas.
UY27604A1 (es) Compuestos químicos.
ES2112377T3 (es) Procedimiento para la preparacion de derivados del taxano y productos intermedios.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
AR027060A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos, asi como el uso deestos compuestos para la fabricacion de medicamentos
MX9401315A (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2067822T3 (es) Inhibidores de la fosfolipasa a2 isoprenoide y preparaciones que los contienen.
ES2098505T3 (es) Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2001923A6 (es) Procedimiento para preparar 3-amino-dihidro-(1)-benzo(tio)piranos.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612741

Country of ref document: ES